RCT: Among patients with rheumatoid arthritis in remission, tapering conventional DMARDs using half-dose resulted in disease flares in 25% of patients compared with 6% of patients in the stable-dose group.
7 May, 2021 | 08:26h | UTCEffect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)
Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly